Although clinical trials of monotherapy with antibodies to TNF-α for various types of cancer have not demonstrated significant efficacy43–46, our findings now suggest that combination therapy with such antibodies and osimertinib is a promising strategy for patients with NSCLC positive for both EGFR and TP53-GOF mutations. Here, TP53 is linked to cancer.